

- 633 Jin Bu Huan Toxicity in Children— Colorado, 1993
- 636 Surveillance for Cholera— Cochabamba Department, Bolivia, January–June 1992
- 645 Cigarette Smoking-Attributable Mortality and Years of Potential Life Lost — United States, 1990
 649 Notice to Readers

MORBIDITY AND MORTALITY WEEKLY REPORT

Epidemiologic Notes and Reports

Jin Bu Huan Toxicity in Children — Colorado, 1993

The consumption of traditional ethnic remedies can have adverse health effects, especially among children (1,2). Life-threatening bradycardia with rapid onset and central nervous system (CNS) and respiratory depression developed in three unrelated children in Colorado during 1993 following ingestion of Jin Bu Huan tablets, a Chinese herbal medicine used for relieving pain. This report summarizes the investigations of these cases.

Patient 1. A 13-month-old boy was lethargic and breathing abnormally when found by his mother approximately 20 minutes after he ingested approximately 60 Jin Bu Huan tablets. His initial vital signs measured by an emergency medical team included a blood pressure of 75/50 mm Hg, pulse of 100, and a respiratory rate of 28. The child exhibited CNS depression and was responsive only to painful stimuli. In the emergency department, he was lethargic, with hypotonia, and had a respiratory rate of 44 and transient bradycardia (pulse mid 40s). He was unresponsive to naloxone (3.8 mg), a fingerstick glucose test measured 110 mg/dL, and an extensive toxicologic screen was negative. He was treated with activated charcoal through an orogastric tube. He became more alert during the next 10 hours until his physical examination and mental status were completely normal. Follow-up indicated no permanent sequelae.

Patient 2. A 2¹/₂-year-old girl was lethargic and breathing abnormally when found by her mother 30–60 minutes after she ingested approximately 17 Jin Bu Huan tablets. Paramedics found the child unresponsive with respiratory depression. An acute episode of bradycardia (pulse 30–35) was successfully treated with atropine. Initial examination in the emergency department indicated miotic pupils (2 mm and equal), CNS depression, and a disconjugate gaze. Blood pressure was palpated at 100 mm Hg systolic; pulse, 100; and respiratory rate, 24. She was unresponsive to naloxone (0.8 mg). The patient's respiratory rate diminished, requiring intubation within 20 minutes after arrival to the emergency department. During the next hour, the child's condition improved, and during an episode of vomiting, she extubated herself. Gastrointestinal decontamination treatment included performing gastric lavage and administering activated charcoal and a cathartic. She remained intermittently

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES / Public Health Service

Jin Bu Huan Toxicity — Continued

lethargic with diffuse muscle weakness until approximately 8 hours following ingestion. Urine and serum toxicologic screens were negative for more than 30 substances including β -blockers, clonidine, and opiates. She was discharged the following day after a complete recovery. Follow-up indicated no permanent sequelae.

Patient 3. A 23-month-old girl was lethargic when found by her parents within 1 hour after she ingested approximately seven Jin Bu Huan tablets. The child was transported to an emergency department $1^{1}/_{4}$ hours following ingestion. Her blood pressure was 94/64 mm Hg and pulse 130. Gastrointestinal decontamination consisted of performing gastric lavage (resulting in recovery of pill fragments) and administering activated charcoal and a cathartic. Approximately 2 hours after ingestion, the child was awake and talkative. She was observed in the emergency department until 5 hours following ingestion and was discharged. Follow-up indicated no permanent sequelae.

Follow-up investigation. Analysis of Jin Bu Huan tablets retrieved from the parents of the three children was performed at Colorado State University using nuclear magnetic resonance and gas chromatography/mass spectroscopy; the tablets were 36% concentrated weight-by-weight levo-tetrahydropalmatine (L-THP), a substance present in the plant genus *Stephania* but not in the genus *Polygala*—the plant of origin indicated on the product package insert (2–4). Each tablet contained 28.8 mg L-THP; no other plant alkaloids were present in tablets tested from multiple bottles of Jin Bu Huan. Extensive toxicologic analysis of the Jin Bu Huan tablets and of urine and serum from patients 1 and 2 did not detect other drugs or pharmaceutical products. As a result of this investigation, Jin Bu Huan anodyne tablets and their active ingredient (L-THP) were entered into the update of Poisindex[®]*, an international toxicologic data base.

Reported by: RS Horowitz, MD, RC Dart, MD, H Gomez, MD, LL Moore, BFulton, Rocky Mountain Poison Center, K Feldhaus, MD, Emergency Dept, Denver General Hospital, J Brent, MD, Denver; FR Stermitz, PhD, JJ Beck, Dept of Chemistry and Agricultural Experiment Station, Colorado State Univ, Fort Collins; JR Alessi, DO, Walsenburg. PAGM de Smet, PhD, Documentation and Information Center, Royal Dutch Association for Advancement of Pharmacy, the Netherlands. Center for Food Safety and Applied Nutrition, Food and Drug Administration. Health Studies Br, Div of Environmental Hazards and Health Effects, National Center for Environmental Health, CDC.

Editorial Note: Traditional Chinese herbal products are widely available in the United States. However, because they are not marketed as a drug, these products have not been subjected to standard tests for safety and effectiveness. Jin Bu Huan is manufactured in China, and the stated ingredients are Polygla Chinensis L. alkaloid (30%) and starch (70%) (*5*,*6*). The insert accompanying Jin Bu Huan anodyne tablets describes its action to be anodyne (analgesic), sedative, antispasmodic, and hypnotic and states it to be "a particularly good remedy for the patient suffering from insomnia due to pain." In addition, it lists specific medical indications for the product including "gastric ulcer, duodenal ulcer pains, stomachic [sic] neuralgia, pain in shrunken womb after childbirth, nervous insomnia, spasmodic cough, etc." Although this product was sold as a dietary supplement in health food stores, claims on the labeling that the product

^{*}Use of trade names and commercial sources is for identification only and does not imply endorsement by the Public Health Service or the U.S. Department of Health and Human Services.

Jin Bu Huan Toxicity — Continued

is for the treatment, prevention, mitigation, or cure of a disease make it subject to regulation as a drug.

The clinical presentations of and findings in the three children described in this report are consistent with those detected in animals exposed to L-THP (7,8). In particular, exposure of animals to L-THP results in sedation, analgesia, neuromuscular blockade, and dopamine receptor antagonism. These studies also have documented L-THP to be naloxone resistant with no affinity for opiate receptors.

As part of this investigation, the Rocky Mountain Poison Center found Jin Bu Huan tablets for sale in health food stores in the Denver metropolitan area. The investigation has not detected evidence of pharmaceutical contamination of this product. However, its potential toxicity may result from a combination of factors, including the extreme potency of L-THP, the misidentification of the plant from which the product was derived, the false and potentially misleading medical claims, the availability of the product, and lack of childproof packaging.

The public health implications associated with the use of herbal products in the United States are potentially great because many persons use such herbs and other unconventional products. For example, a recent study of the prevalence and frequency of use of unconventional therapy in the United States indicated that 3% of adult respondents reported using an herbal medicine during the preceding year (9). In addition, a study in the United States of dietary supplement advertising indicated that 22% of these products did not list ingredients in their advertisements (10). The investigation of the three cases in this report does not provide an adequate basis for assessing the health impact of these products; however, the severity of the adverse health effects in these three cases underscores the potential health risks associated with use of these herbal and other botanical products.

To prevent cases of unintentional poisoning associated with herbal and other botanical products, such products should be sold in childproof packaging and kept in childproof containers, and parents should be informed about the potential toxicity of these products. In addition, accurate labeling of the active ingredient is critical to enable prompt and proper medical treatment for unintentional poisoning.

References

- 1. CDC. Lead poisoning associated with use of traditional ethnic remedies—California, 1991–1992. MMWR 1993;42:521–4.
- 2. De Smet PAGM, Elferink F, Verpoorte R. Left-turning tetrahydropalmatine in Chinese tablets [Dutch]. Ned Tijdschr Geneeskd 1989;133:308.
- 3. Ghosal S, Chauhan RPS, Srivastava RS. Structure of chinensin: a new lignan lactone from *Polygala chinensis*. Phytochemistry 1974;13:2281–4.
- 4. Tomita M, Kozuka M, Uyeo S. Studies on the alkaloids of menispermaceous plants, CCXXII: alkaloids of *Stephania rotunda* loureiro (suppl 1) [Japanese]. J Pharm Soc Jap 1966;86:460–6.
- 5. Zhen-Gang W, Gan-Zhong L. Advances in natural products in China. Trends in Pharmacological Sciences 1985;6:423–6.
- 6. Ding GS. Important Chinese herbal remedies. Clin Ther 1987;9:345-57.
- 7. Lui GQ, Algeri S, Garattini S. D-L-tetrahydropalmatine as monoamine depleter. Arch Int Pharmacodyn Ther 1982;258:39–50.
- 8. Marcenac F, Jin GZ, Gonon F. Effect of L-tetrahydropalmatine of dopamine release and metabolism in the rat striatum. Psychopharmacology 1986;89:89–93.
- 9. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. N Engl J Med 1993;328:246–52.

Jin Bu Huan Toxicity — Continued

10. Philen RM, Ortiz DI, Auerback SB, Falk H. Survey of advertising for nutritional supplements in health and bodybuilding magazines. JAMA 1992;268:1008–11.

International Notes

Surveillance for Cholera — Cochabamba Department, Bolivia, January–June 1992

Following the epidemic spread of cholera in Peru (1), in April 1991, health officials in neighboring Bolivia established a surveillance system to detect the appearance and monitor the spread of cholera in their country. The first confirmed case in Bolivia was reported on August 26, 1991; by December 31, 1991, a total of 206 cases had been reported, and 21,324 probable and confirmed cases were reported during 1992. This report summarizes cholera surveillance in Cochabamba department (1992 population: 1,070,000) in central Bolivia (Figure 1) for January–June 1992; the assessment was one element of the Data for Decision Making (DDM) Project conducted by the Child and Community Health Project, Bolivia's Ministry of Social Security and Public Health (MSSPH), the U.S. Agency for International Development (USAID), and CDC.

In April 1991, the MSSPH established three categories of case definitions for cholera surveillance: 1) suspected—acute diarrhea in a person living in an area where *Vibrio cholerae* O1 had not been reported previously (stool cultures were obtained from patients with suspected cases); 2) probable—diarrhea with dehydration, vomiting, and leg cramps in a person living in an area with reported cholera cases or related




FIGURE 1. Location of Cochabamba department, Bolivia

Cholera — Continued

epidemiologically to another person with cholera (stool cultures were not recommended for patients with probable cases); and 3) confirmed—diarrhea in a person with a stool culture positive for *V. cholerae* O1. A two-page case-report form was designed for tabulating and investigating each case and was distributed to all health units in the country. In July 1992, the two-page cholera surveillance form was replaced by a quarter-page surveillance form that collected data on fewer variables.

Cases reported during January 1–June 30, 1992, were analyzed. During this period, 4087 cholera cases in residents of Cochabamba department were reported to the MSSPH; surveillance forms were submitted for 2962 (72%) and oral reports for 1125 (28%) cases. Data about the 2962 cases reported on the surveillance form were used to evaluate the form and to characterize the epidemiology of cholera in Cochabamba department. Of the forms received, data on patient's age, sex, address, and outcome were available for 97% of reported cases; however, information on signs and symptoms of illness was reported for approximately 63% of cases.

The 2962 reported cases included 2667 classified as probable and 295 classified as confirmed and represented an incidence of 2.8 per 1000 population in Cochabamba department. Of the 2962 persons, 1527 (52%) were male (Table 1); 2539 (86%) were aged \geq 15 years, and 157 (5%) were aged <5 years. A total of 1621 (55%) cases occurred in residents of urban areas and 1341 (45%) in residents of rural areas. Of 2878 patients for whom hospitalization status was known, 2449 (85%) were hospitalized; hospitalization rates were similar in urban (83%) and rural (87%) areas. Forty-three persons died (overall case-fatality rate [CFR]=1.4%). Thirteen deaths occurred among all urban cases (CFR=0.8% for urban areas), and 30 deaths occurred among 1328 reported rural cases (CFR=2.2% for rural areas).

Reported by: G Pereira, MD, Ministry of Social Security and Public Health, La Paz; Child and Community Health Project, La Paz; J Flores, MD, Chief of Epidemiology, R Agudo, Health Unit, Cochabamba; US Agency for International Development, Bolivia. US Agency for International Development, Washington, DC. Pan American Health Organization, Washington, DC. Data for Decision Making Project, International Br, Div of Field Epidemiology, Epidemiology Program Office; Foodborne and Diarrheal Diseases Br, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases; Div of Field Svcs, International Health Program Office, CDC.

Age group (yrs)	Female	Male	Total	Age-specific incidence rate
<1	7	11	18	0.4
1- 4	63	76	139	1.1
5–14	86	108	194	0.7
15–29	327	391	718	2.5
30–44	326	352	678	4.2
45–59	277	281	558	5.3
≥60	309	271	580	6.5
Unknown	40	37	77	_
Total	1435	1527	2962	2.7

TABLE 1. Number of reported cholera cases, by patient age group, sex, and age-specific incidence rates* — Cochabamba department, Bolivia, January 1–June 30, 1992

*Per 1000 persons.

Cholera — Continued

Editorial Note: Features of the cholera epidemic in Bolivia have been similar to those in neighboring countries: the disease has predominantly affected adults in both rural and urban areas (1). The overall CFR for cholera in Latin America has been approximately 1% (2)—lower than that in other epidemics (3). The CFR has been higher in rural areas of Latin America (as demonstrated in Cochabamba department), reflecting factors such as lack of access to health care, inadequate distribution of oral rehydration salts, and delays in providing prevention and treatment education outside urban areas (4).

The challenges associated with cholera surveillance in Bolivia are similar to those in other Latin American countries that initiated cholera prevention and control programs after the epidemic began in Peru. For example, surveillance systems established to detect and investigate the earliest cases initially were effective; however, as the number of cases increased, available resources for reporting were strained because 1) complex case definitions constrained reporting and interpretation of data; 2) lengthy and detailed surveillance forms that were useful in investigating the earliest cases were subsequently unnecessary and cumbersome (in Cochabamba department, reporting using the two-page form was considered incomplete, inefficient, and was often delayed for cases in rural areas; essential data elements could be listed on the guarter-page form, and since its introduction, all cholera cases reported to the MSSPH have been reported with the form); and 3) laboratories in areas of intense cholera activity were inundated by requests for cultures to confirm suspect cases. CDC and the Pan American Health Organization have recommended measures to simplify cholera surveillance and facilitate rapid dissemination of surveillance information for Latin America and the Caribbean (see box) (5).

Analysis of surveillance information at levels below the national level provides health authorities with more immediate information on local disease activity, allowing appropriate decisions to be made regarding the distribution of treatment supplies and/or support personnel. The evaluation of cholera surveillance in Cochabamba department for January–June 1992 is a component of the DDM Project in Bolivia. The USAID-funded DDM Project, in which Bolivia is one of five countries collaborating with CDC, aims to increase data-based decision making in public health for formulating health policies and for program planning, monitoring, and evaluation. In 1992, the MSSPH requested assistance from USAID/Bolivia and CDC to provide training to 41 national, regional, and district program managers, epidemiologists, and other health officials in applied epidemiology, management, biostatistics, and communication skills. The evaluation of cholera surveillance in Cochabamba department was one of the 41 applied epidemiology projects conducted as part of this training program. The results of the evaluation described in this report have been used to strengthen cholera surveillance efforts and prevention activities in Bolivia.

References

- 1. Pan American Health Organization. Cholera situation in the Americas: an update. Epidemiol Bull 1991;12:11.
- 2. CDC. Update: cholera—Western Hemisphere, 1992. MMWR 1993;42:89-91.
- 3. Glass RÍ, Black RE. The epidemiology of cholera. In: Barua D, Greenbough WB III, eds. Cholera. New York: Plenum, 1992.
- 4. Quick RE, Vargas R, Moreno D, et al. Epidemic cholera in the Amazon: thechallenge of preventing death. Am J Trop Med Hyg 1993;48:597–602.

Cholera — Continued

5. Vugia DJ, Koehler JE, Ries AA. Surveillance for epidemic cholera in the Americas: an assessment. MMWR 1992;41(no. SS-1):27–34.

Recommended Measures for Cholera Surveillance and Rapid Surveillance Information Dissemination for Latin America and the Caribbean

Case definitions. Two categories should be used in case definitions in areas with epidemic cholera: clinical and laboratory-confirmed. A clinical case should be defined as acute, watery diarrhea in a person aged \geq 5 years; a laboratory-confirmed case, as culture-confirmed *Vibrio cholerae* O1 infection in a person with diarrhea.


Report forms. Lengthy surveillance forms should not be used. Basic data (e.g., age, sex, address, date of onset or treatment, hospitalization, and outcome) can be collected using short forms and kept for analysis at the local level.

Laboratory confirmation of cases. Cultures should be performed for clinical cholera cases in a cholera-threatened area. After cholera has become established in an area, stool cultures should be performed at a reduced frequency (e.g., 10 cultures per month) to confirm the continuing presence of *V. cholerae* O1 and to monitor antimicrobial resistance.

Surveillance during an evolving epidemic. In areas threatened by cholera, acute dehydrating diarrhea in persons aged \geq 5 years should be investigated and cultured. When small numbers of cases are being confirmed, only laboratory-confirmed cases should be reported. When the number of laboratory-confirmed cases increases, the clinical case definition should be used for reporting, and culturing should be used only on a limited basis to confirm the continuing presence of cholera. As the number of cholera cases decreases, the definition for clinical cases should be used for at least 1 year to detect seasonal recurrences of the epidemic. To determine routes of cholera transmission and the potential for prevention, case-control investigations should be conducted at outbreak sites.

Analysis and communication of surveillance data. Surveillance data (e.g., numbers of cases, hospitalizations, and deaths) should be transmitted weekly to the central level and analyzed in a timely manner. Summary reports should be disseminated regularly to all components of and levels within the surveillance system and to the Pan American Health Organization.

FIGURE I. Notifiable disease reports, comparison of 4-week totals ending August 21, 1993, with historical data — United States



*The large apparent decrease in reported cases of measles(total) reflects dramatic fluctuations in the historical baseline.

[†]Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where thehatched area begins is based on the mean and two standard deviations of these 4-week totals.

	Cum. 1993		Cum. 1993
AIDS* Anthrax Botulism: Foodborne Infant Other Brucellosis Cholera Congenital rubella syndrome Diphtheria Encephalitis, post-infectious Gonorrhea Haemophilus influenzae (invasive disease) [†] Hansen Disease	67,732 8 25 2 60 15 7 - 107 240,441 791 105	Measles: imported indigenous Plague Poliomyelitis, Paralytic [§] Psittacosis Rabies, human Syphilis, primary & secondary Syphilis, congenital, age < 1 year [¶] Tetanus Toxic shock syndrome Trichinosis Tuberculosis Tubarculosis	30 192 7 - 35 1 16,264 677 25 157 9 12,950 86
Leptospirosis Lyme Disease	25 3,946	Typhoid fever Typhus fever, tickborne (RMSF)	199 239

TABLE I. Summary — cases of specified notifiable diseases, United States, cumulative, week ending August 21, 1993 (33rd Week)

*Updated monthly; last update July 31, 1993. [†]Of 732 cases of known age, 240 (33%) were reported among children less than 5 years of age. [§]Two (2) cases of suspected poliomyelitis have been reported in 1993; 4 of the 5 suspected cases with onset in 1992 were confirmed; the confirmed cases were vaccine associated.

[¶]Reports through first quarter of 1993.

Reporting Area Asspit: Multi- guits Encephallits Primary 1993 Count- Feedback Hepatitis (Viral, by type A Legionet- B Legionet- fied Legionet- f
Reporting Area 1943 1993 1903 104 1 1 1 1 1 1 1 1 1 1 <t< th=""></t<>
1993 1993 1993 1993 1992 1993 193 193 193 193 193
$\begin{array}{c c c c c c c c c c c c c c c c c c c $
Maine 94 20 1 - 55 60 10 9 2 - 4 55 VI. 14 20 3 - 17 16 3 7 2 - - 33 Mass. 1.818 69 5 3 1.864 2.353 157 218 57 7 22 - - 33 MID. ATLANTIC 15.598 435 35 7 28.398 3.647 691 216 4 147 2.118 Myster NY. 2.373 212 24 4 4.903 1.698 171 1 - 3 3 1.618 1.718 1.469 10 205 - 2.23 457 7 2.2 1.4 4.698 1.77 196 139 32 - 105 18 N.L 2.99 10 0 3 10.757 176 139 32
Vt.14203.17163723Mass.18695318642,3531572185772210R.I.219272.253457561674158Conn.1,02028,39833,64769191521641472,115Upstate N.Y.2,3732122444,49936,7452312651341451,188N.Y. City8,29910417,80811,698107121133N.J.2,9914,7744,698190269562376467E.N. CENTRAL5,4199121062046,20957,8531,4789404301020031Indi </td
Mass.1.818 R1.69 215 231.864 2.953 2.9544.57 2.657 6.667 6.77 4.73822 4.738MID. ATLANTIC15.598 10.954435 4.35357 4.442.8398 4.993 4.7483.647 4.993 6.7446.91 6.91 2.15216 2.164 4.147 4.147 4.147 4.147 2.115NJ.2.991 2.991 P.a 4.774 4.6484.4993 4.993 4.744 4.6481 4.6491 5.050693 9.200 2.2025 2.60- 2.3 4.577 4.074P.A.1.945 1.948119 1010 310,751 10,50610,506 1.050693 9.200 2.2025 2.00- 2.002.3 4.070Oho938 1.04350 1.07536 1.07511.478 1.0506940 1.3932 3.20- 1.075100 1.075Oho938 1.0350350 2.7263.679 3.781.478 3.90 3.204.00 3.000.00 3.1Ohio6.344 1.12212 2.8 1.03713.622 1.64971.4692 3.731.570 3.201.64 3.201.478 3.206.40 4.00Mich.1.379 1.0372.54 2.7262.726 3.083.22 2.783.20 3.206.40 4.416 4.10Vin. CENTRAL 1.0412.428 2.7473.71 3.4881.10 2.7763.757 3.4844.61 4.411.50 4.41Obak.1.141 1.07- - - - - - - - - - - - - - -<
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
E.N. CENTRAL5,4199121062046,20957,8531,4789404301020031Ohio93835036414,00517,50719613932-10518Ind.1.93915821213,02218,67937315939310200Mich.1.37925427610,73913,4881322783206406Wis.5292810-3,5502,72630822231-8-Minn.511617-1.6141,8452844634150Iowa1,3741077,0879,1129882886761177Mo.1,3741077,0879,1129882886761177N. Dak.11034761,0701351182234Kans.2441072-2,4093,225614210-5233521Del.25340313022233110251Md.1,63013918-10,2049,7751121809529101251Del.2
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
Wis. 529 28 10 - 3,550 2,726 308 222 31 - 8 - W.N. CENTRAL 2,428 371 18 - 12,390 16,482 1,570 404 94 11 48 93 Minn. 511 61 7 - 1,614 1,845 284 46 3 4 1 50 Iowa 141 67 1 - 602 1,066 29 17 6 1 7 7 Mo. 1,374 107 - - 7087 9,112 988 288 67 6 11 7 N.Dak. 12 10 3 - 2476 1070 135 11 8 - 23 44 Kans. 224 40 3 - 476 1070 135 112 86 - 10 251 Del.
$\begin{array}{cccccccccccccccccccccccccccccccccccc$
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
S. Dak.22125-17311013Nebr.13574761,070135118-234Kans.2441072-2,4093,225614210-523S. ATLANTIC14,2791,428804664,23395,3297831,45340548130521Del.2534038141,102811286-10251Md.1,63013918-10,2049,7751121809529101D.C.896263,1064,266633132W. Va.461718-38757292717-14N.C.79013412-16,27015,8114020048-1660S.C.933206,7407,097103331137Ga.1,8548414,66028,7006613255-2629Fla.6,82883114014,59217,198436642165221925E.S. CENTRAL1,79640715727,88
Kans. 244 107 2 - 2,409 3,225 61 42 10 - 5 23 S. ATLANTIC 14,279 1,428 80 46 64,233 95,329 783 1,453 405 48 130 521 Del. 253 40 3 - 884 1,102 8 112 86 - 10 251 Md. 1,630 139 18 - 10,204 9,775 112 180 9 5 29 101 D.C. 896 26 - - 3,106 4,266 6 33 - -13 22 Va. 1,049 137 27 6 7,390 10,808 96 94 22 20 3 42 W. Va. 46 17 18 - 387 572 9 27 17 - 16 60 S.C. 933 20 - - 6,740 70,97 10 33 3 1<
S. ATLANTIC14,2791,428804664,23395,3297831,45340548130521Del.253403-8841,102811286-10251Md.1,63013918-10,2049,7751121809529101D.C.896263,1064,266633132Va.10,491372767,39010,80896942220342W. Va.461718-38757292717-14N.C.79013412-16,27015,8114020048-1660S.C.933206,7407,097103331137Ga.1,854841-4,66028,7006613255-2629Fla.6,82883114014,59217,198436642165221925E.S. CENTRAL1,79640715727,88329,812165808568131133Ky.213153762,9883,042795910-1133Ks.3214921
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$
Ga. 1,854 84 1 - 4,660 28,700 66 132 55 - 26 29 Fla. 6,828 831 1 40 14,592 17,198 436 642 165 22 19 25 E.S. CENTRAL 1,796 407 15 7 27,883 29,812 165 808 568 1 31 13 Ky. 213 153 7 6 2,988 3,042 79 59 10 - 11 3 Tenn. 731 91 5 - 8,363 9,820 33 673 544 - 13 8 Ala. 531 114 1 - 10,119 9,695 35 71 4 1 2 2 Miss. 321 49 2 1 6,413 7,255 18 5 10 - 5 - W.S. CENTRAL 6,957 640 26 2 28,302 33,675 1,289 1,021<
E.S. CENTRAL 1,796 407 15 7 27,883 29,812 165 808 568 1 31 13 Ky. 213 153 7 6 2,988 3,042 79 59 10 - 11 3 Tenn. 731 91 5 - 8,363 9,820 33 673 544 - 13 8 Ala. 531 114 1 - 10,119 9,695 35 71 4 1 2 2 Miss. 321 49 2 1 6,413 7,255 18 5 10 - 5 - W.S. CENTRAL 6,957 640 26 2 28,302 33,675 1,289 1,021 173 115 20 29 Ark. 267 34 1 - 5,428 4,866 34 36 2 2 2 1 La. 921 44 1 - 7,393 9,888 52 134 <t< td=""></t<>
Ky. 213 153 7 6 2,988 3,042 79 59 10 - 11 3 Tenn. 731 91 5 - 8,363 9,820 33 673 544 - 13 8 Ala. 531 114 1 - 10,119 9,695 35 71 4 1 2 2 Miss. 321 49 2 1 6,413 7,255 18 5 10 - 5 - W.S. CENTRAL 6,957 640 26 2 28,302 33,675 1,289 1,021 173 115 20 29 Ark. 267 34 1 - 5,428 4,866 34 36 2 2 2 1 La. 921 44 1 - 7,393 9,888 52 134 65 2 2 - Okla. 590 1 6 - 2,191 3,407 95 189 64 <t< td=""></t<>
Ala. 531 114 1 - 10,119 9,695 35 71 4 1 2 2 Miss. 321 49 2 1 6,413 7,255 18 5 10 - 5 - W.S. CENTRAL 6,957 640 26 2 28,302 33,675 1,289 1,021 173 115 20 29 Ark. 267 34 1 - 5,428 4,866 34 36 2 2 2 1 La. 921 44 1 - 7,393 9,888 52 134 65 2 2 - Okla. 590 1 6 - 2,191 3,407 95 189 64 7 11 16
Miss. 321 49 2 1 6,413 7,255 18 5 10 - 5 - W.S. CENTRAL 6,957 640 26 2 28,302 33,675 1,289 1,021 173 115 20 29 Ark. 267 34 1 - 5,428 4,866 34 36 2 2 2 1 La. 921 44 1 - 7,393 9,888 52 134 65 2 2 2 - Okla. 590 1 6 - 2,191 3,407 95 189 64 7 11 16
Ark. 267 34 1 - 5,428 4,866 34 36 2 2 2 1 La. 921 44 1 - 7,393 9,888 52 134 65 2 2 - Okla. 590 1 6 - 2,191 3,407 95 189 64 7 11 16
La. 921 44 1 - 7,393 9,888 52 134 65 2 2 - Okla. 590 1 6 - 2,191 3,407 95 189 64 7 11 16
Tex. 5,179 561 18 2 13,290 15,514 1,108 662 42 104 5 12
MOUNTAIN 2,948 389 16 4 6,901 7,730 2,600 375 199 56 52 16
Mont. 22 - 1 47 67 57 4 2 - 5 - Idaho 52 7 - 108 67 122 33 - 1 1 2
Wyo. 31 5 - 57 35 11 15 55 - 5 8
N. Mex. 240 70 3 2 584 562 242 142 66 2 3 -
Ariz. 992 127 5 - 2,588 2,662 925 58 10 9 10 - Utah 197 25 1 - 219 198 536 37 24 11 7 2
Nev. 429 45 1 1 1,180 1,321 71 35 7 1 15 4
PACIFIC 15,075 1,375 100 16 20,945 29,019 4,415 1,456 554 130 73 79 Wash. 1,008 - 1 - 2,445 2,562 498 143 124 8 9 3
Oreg. 575 1,079 1,090 63 22 10 2
Calif. 13,233 1,290 95 16 16,735 24,618 3,302 1,266 409 119 58 73 Alaska 47 14 3 - 339 445 498 8 9 - - -
Hawaii 212 71 1 - 347 304 54 17 2 3 6 1
Guam - 2 38 48 2 2 - 1 P.R. 1,950 35 318 129 52 239 41 2
V.I. 34 71 67 - 2 Amer. Samoa 34 27 13
C.N.M.I 2 55 56 - 1 - 1

TABLE II. Cases of selected notifiable diseases, United States, weeks endingAugust 21, 1993, and August 15, 1992 (33rd Week)

N: Not notifiable U: Unavailable *Updated monthly; last update July 31, 1993. C.N.M.I.: Commonwealth of Northern Mariana Islands

		Measles (Rubeola) Menin-													
	Malaria	lus ali ar				Tatal	Menin- gococcal	Mu	mps	I	Pertussi	s		Rubella	1
Reporting Area	Malaria	inaig	enous	impo	orted*	Total	Infections				0	0		0	0
	Cum. 1993	1993	Cum. 1993	1993	Cum. 1993	Cum. 1992	Cum. 1993	1993	Cum. 1993	1993	Cum. 1993	Cum. 1992	1993	Cum. 1993	Cum. 1992
UNITED STATES	684	6	192	-	30	2,098	1,626	16	1,095	146	2,467	1,403	2	140	128
NEW ENGLAND Maine	52 1	2 1	55 1	-	4	55 3	93 5	-	8	6 1	475 11	105 4	-	1 1	6 1
N.H.	6	-	1	-	-	13	12	-	-	-	214	30	-	-	-
Vt. Mass.	1 25	- 1	30 14	-	1 2	14	4 52	-	- 2	1	55 148	3 45	-	-	-
R.I. Conn.	2 17	-	- 9	-	1	21 4	1 19	-	2 4	3 1	6 41	- 23	-	-	4 1
MID. ATLANTIC	107	-	7	_	3	196	196	2	86	23	293	65	_	41	10
Upstate N.Y.	38	-	-	-	1	111	89	2	31	9	119	31	-	8	7
N.Y. City N.J.	24 29	-	2 5	-	- 2	49 36	19 31	-	- 8	-	7 35	9 25	-	15 13	- 3
Pa.	16	-	-	-	-	-	57	-	47	14	132	-	-	5	-
E.N. CENTRAL Ohio	43 9	-	14 5	-	2	48 6	258 76	1 1	151 59	32 25	439 199	196 42	1	4 1	9
Ind.	3	-	-	-	-	20	43	-	3	4	46	19	-	-	-
III. Mich.	24 7	-	5 4	-	- 1	15 4	69 42	-	37 49	- 3	53 27	26 8	- 1	- 2	8 1
Wis.	-	-	-	-	1	3	28	-	3	-	114	101	-	1	-
W.N. CENTRAL Minn.	18 4	-	1	-	2	11 10	108 6	1	33 1	11	197 83	112 33	-	1	7
lowa	1	-	-	-	-	1	18	-	7	7	11	3	-	-	2
Mo. N. Dak.	5 2	-	1	-	-	-	43 3	1 -	19 5	3	72 3	49 11	-	1	1
S. Dak.	2	-	-	- U	-	-	3		- 1	1	7	5	-	-	-
Nebr. Kans.	3 1	U U	-	U	2	-	8 27	U U	-	U U	8 13	5 6	U U	-	4
S. ATLANTIC	191	4	21	-	3	119	308	5	349	11	279	93	-	8	13
Del. Md.	2 21	-	-	-	- 2	1 16	11 37	-3	4 65	1 8	8 98	3 14	-	2 2	- 5
D.C. Va.	6 19	-	-	-	- 1	- 14	5 26	-	- 17	-	2 35	1	-	-	-
W. Va.	2	-	-	-	-	-	11	1	12	-	10	6	-	-	1
N.C. S.C.	89 1	-	-	-	-	24 29	55 28	-	195 14	-	44 8	22 9	-	-	- 2
Ga.	11	-	-	-	-	-	69	-	14	2	14	8	-	-	-
Fla. E.S. CENTRAL	40 21	4	21 1	-	-	35 460	66 101	1 2	28 39	-	60 110	24 20	-	4	5 1
Ky.	4	-	-	-	-	443	19	-	-	-	8	-	-	-	-
Tenn. Ala.	7	-	-	-	-	-	24 34	- 1	11 21	-	54 42	5 13	-	-	1
Miss.	4	-	-	-	-	17	24	1	7	-	6	2	-	-	-
W.S. CENTRAL Ark.	15 2	-	2	-	3	1,079	140 16	4	160 4	8	87 7	168 8	1	17	6
La.	2	-	- 1	-	-	-	27	-	12	-	6	4	-	- 1	-
Okla. Tex.	4 7	-	-	-	- 3	11 1,068	23 74	-	8 136	5 3	52 22	27 129	- 1	1 15	- 6
MOUNTAIN	25	-	3	-	-	25	131	-	43	15	228	230		6	5
Mont.	2	-	-	-	-	-	11 9	-	- 5	1	2 67	3 27	-	- 1	- 1
ldaho Wyo.	1	-	-	-	-	1	2	-	2	-	1	-	-	-	-
Colo. N. Mex.	15 5	-	2	-	-	20 2	23 4	- N	12 N	6 2	69 28	27 54	-	-	-
Ariz.	-	-	-	-	-	2	63	-	7	1	38	94	-	2	2
Utah Nev.	- 2	-	-	-	-	-	12 7	-	3 14	4 1	22 1	24 1	-	2 1	1 1
PACIFIC	212	-	88	-	13	105	291	1	226	40	359	414	-	62	71
Wash. Oreg.	21 4	-	-	-	-	10 3	50 22	1 N	10 N	6 1	33 10	123 23	-	- 2	6 1
Calif.	182	-	77	-	4	54	198	-	192	33	303	246	-	35	43
Alaska Hawaii	1 4	-	- 11	-	1 8	9 29	13 8	-	6 18	-	3 10	5 17	-	1 24	- 21
Guam	1	U	2	U	-	10	1	U	6	U	-	-	U	-	1
P.R. V.I.	-	-	224	-	-	293	7	-	2 3	-	2	9	-	-	-
Amer. Samoa	-	-	1	-	-	-	-	-	-	-	2	6	-	-	-
C.N.M.I.	-	-	-	-	1	2	- internationa	-	12	-	-	1	-	-	-

TABLE II. (Cont'd.) Cases of selected notifiable diseases, United States, weeks ending August 21, 1993, and August 15, 1992 (33rd Week)

*For measles only, imported cases include both out-of-state and international importations. N: Not notifiable U: Unavailable [†] International [§] Out-of-state

Reporting Area		bhilis Secondary)	Toxic- Shock Syndrome	Tuber	culosis	Tula- remia	Typhoid Fever	Typhus Fever (Tick-borne) (RMSF)	Rabies, Animal
····p ·····g · ····	Cum. 1993	Cum. 1992	Cum. 1993	Cum. 1993	Cum. 1992	Cum. 1993	Cum. 1993	Cum. 1993	Cum. 1993
UNITED STATES	16,264	21,596	157	12,950	14,062	86	199	239	5,232
NEW ENGLAND	260	417	10	290	242	-	18	2	905
Maine N.H.	3 25	2 29	2 2	15 9	17 3	-	- 1	-	- 58
Vt.	1	1	1	3	4	-	-	-	19
Mass. R.I.	99 11	203 21	4 1	156 34	106 23	-	12	2	348
Conn.	121	161	-	73	89	-	5	-	480
MID. ATLANTIC	1,512	3,116	28	3,026	3,401	1	44	22	1,980
Upstate N.Y. N.Y. City	130 781	231 1,745	15 1	313 1,782	426 2,003	1	9 26	4	1,506
N.J.	210	403	-	484	572	-	6	10	264
Pa.	391	737	12	447	400	-	3	8	210
E.N. CENTRAL Ohio	2,432 753	3,219 506	41 19	1,242 204	1,393 213	4 1	21 5	10 6	60 4
Ind.	202	165	1	135	104	1	1	1	5
III. Mich.	814 387	1,419 629	5 16	569 274	709 307	1 1	10 4	1 2	9 8
Wis.	276	500	-	60	60	-	1	-	34
W.N. CENTRAL	1,010	893	9	302	343	28	2	13	235
Minn. Iowa	51 32	55 35	2 5	38 36	99 25	-	-	1 4	34 41
Mo.	820	688	-	161	153	10	2	6	8
N. Dak. S. Dak.	1 1	1	-	5 11	5 14	- 14	-	- 2	49 32
Nebr.	10	21	-	14	14	1	-	-	7
Kans.	95	93	2	37	33	3	-	-	64
S. ATLANTIC Del.	4,425 83	5,965 137	18 1	2,248 30	2,573 25	2	27 1	108 1	1,293 106
Md.	250	428	-	251	203	-	5	8	387
D.C. Va.	237 420	268 489	- 6	112 281	84 195	-	- 3	- 6	13 231
W. Va.	8	13	-	51	62	-	-	4	58
N.C. S.C.	1,238 643	1,530 823	3	324 263	318 253	1	1	57 8	54 104
Ga.	745	1,195	2	485	565	-	1	19	298
Fla.	801	1,082	6	451	868	1	16	5	42
E.S. CENTRAL	2,472 208	2,749 94	8 2	836 244	916 249	4	4 1	25 5	70 10
Ky. Tenn.	690	764	2 3	144	249	3	1	13	-
Ala. Miss.	547 1,027	1,006 885	2 1	305 143	252 171	1	2	3 4	60
W.S. CENTRAL	3,427	3,722	2	143	1,474	33	2	53	365
Ark.	530	571	-	120	103	19	-	1	18
La. Okla.	1,589 265	1,606 177	- 2	- 171	107 95	- 11	1	1 50	4 54
Tex.	1,043	1,368	-	1,180	1,169	3	1	1	289
MOUNTAIN	153	242	9	296	373	9	7	6	104
Mont. Idaho	1	7 1	- 1	15 8	- 14	5	-	1	16 5
Wyo.	6	3	-	2	-	2	-	5	13
Colo.	41 21	36 27	2	8	30	- 1	5	-	9
N. Mex. Ariz.	68	120	- 1	35 140	52 172	-	2	-	6 46
Utah	4	7	4	17	51	1	-	-	2 7
Nev. PACIFIC	12 573	41 1,273	1 32	71 3,239	54 3,347	- 5	- 74	-	220
Wash.	36	62	6	149	191	1	4	-	- 220
Oreg. Calif.	50 478	27	-	72	82	2	- 67	-	-
Alaska	478	1,175 4	26	2,819 33	2,873 44	2	- 67	-	203 17
Hawaii	3	5	-	166	157	-	3	-	-
Guam	1	3	-	28	54	-	-	-	-
P.R. V.I.	348 31	203 43	-	152 2	135 3	-	-	-	28
Amer. Samoa	-	-	-	2	-	-	-	-	-
C.N.M.I.	3	5	-	19	42	-	-	-	-

TABLE II. (Cont'd.) Cases of selected notifiable diseases, United States, weeks ending
August 21, 1993, and August 15, 1992 (33rd Week)

U: Unavailable

	All Causes, By Age (Years)					P&I [†]		All Causes, By Age (Years)							
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	P&l [†] Total
NEW ENGLAND Boston, Mass. Bridgeport, Conn. Cambridge, Mass. Fall River, Mass. Hartford, Conn. Lowell, Mass. Lynn, Mass. New Bedford, Mass New Haven, Conn. Providence, R.I. Somerville, Mass. Springfield, Mass. Waterbury, Conn.	568 158 43 19 27 55 23 13 5. 24 39 41 4 39 27	371 88 33 14 19 37 16 8 18 27 27 27 22 3 22	3 6 4 3 8 11 1 7	58 18 2 2 9 2 2 2 2 3 - 4 3	16 6 - 1 - 2 - 3 2	16 7 2 1 1 - 3	37 16 - - - 3 6 - - 4	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla. Miami, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, Fla. Tampa, Fla. Washington, Dcl.	164 203 9	706 73 98 51 87 57 33 U 49 34 113 105 6	248 26 28 27 25 26 14 U 16 9 29 45 3	148 23 21 14 8 20 5 U 11 2 15 29	45 2 4 3 4 3 6 U 3 2 4 14	37 6 8 2 3 2 U 2 2 3 9	61 4 14 2 8 U 6 2 14 3 -
Worcester, Mass. MID. ATLANTIC Albany, N.Y. Allentown, Pa. Buffalo, N.Y. Camden, N.J. Elizabeth, N.J. Erie, Pa.§	56 2,111 40 23 100 40 25 35	45 1,374 30 16 68 32 20 26	4 380 6 19 4 4 7	3 261 3 1 8 1 -	2 57 - 3 1 - 1	2 38 1 - 2 2 1	7 97 3 - 3 5 1 2	E.S. CENTRAL Birmingham, Ala. Chattanooga, Tenn. Knoxville, Tenn. Lexington, Ky. Memphis, Tenn. Mobile, Ala. Montgomery, Ala. Nashville, Tenn.	700 103 56 83 67 178 52 38 123	441 67 38 58 46 111 36 26 59	143 20 10 18 10 34 9 5 37	59 10 5 3 5 16 4 4 12	31 3 4 2 6 3 2 10	26 3 2 4 11 - 1 5	47 5 5 6 19 4 2 2
Jersey City, N.J. New York City, N.Y. Newark, N.J. Paterson, N.J. Philadelphia, Pa. Pittsburgh, Pa.§ Reading, Pa. Rochester, N.Y. Schenectady, N.Y. Scranton, Pa.§ Syracuse, N.Y. Trenton, N.J. Utica, N.Y. Yonkers, N.Y.	39	25 858 18 12 0 61 4 78 10 21 49 15 12 19	5 252 11 9 U 20 - 15 1 3 11 4 1	5 192 12 9 U 6 1 9 1 1 6 2 - 3	35 4 1 5 - 2 - 3 - 2	4 20 1 2 - 4 - - -	51 10 1 0 6 - 8 - 5 - 2	W.S. CENTRAL Austin, Tex. Baton Rouge, La. Corpus Christi, Tex Dallas, Tex. El Paso, Tex. Ft. Worth, Tex. Houston, Tex. Little Rock, Ark. New Orleans, La. San Antonio, Tex. Shreveport, La. Tulsa, Okla.	1,413 63 36	882 45 22 32 120 45 68 187 44 76 121 50 72	299 12 8 11 34 14 19 86 16 35 37 5 22	143 4 3 22 12 7 47 47 47 16 15 4 9	52 1 2 4 2 2 13 3 5 9 5 6	37 1 4 1 4 13 5 4 1 3	68 3 4 4 2 30 5 7 6 4
E.N. CENTRAL Akron, Ohio Canton, Ohio Chicago, III. Cincinnati, Ohio Cleveland, Ohio Columbus, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind. Gary, Ind. Grand Rapids, Mich Indianapolis, Ind. Madison, Wis. Milwaukee, Wis. Peoria, III. Rockford, III. South Bend, Ind. Toledo, Ohio Youngstown, Ohio W.N. CENTRAL Des Moines, Iowa Duluth, Minn. Kansas City, Kans. Kansas City, Kans. Minneapolis, Minn. Omaha, Nebr.	206 42 119 58 49 54 104 45 754 99 333 33 33 108 31	$\begin{array}{c} 1,386\\ 56\\ 25\\ 204\\ 93\\ 74\\ 122\\ 87\\ 123\\ 29\\ 42\\ 10\\ 35\\ 139\\ 92\\ 34\\ 37\\ 43\\ 70\\ 38\\ 517\\ 76\\ 26\\ 23\\ 70\\ 25\\ 88\\ 84\\ 88\\ 88\\ 88\\ 88\\ 88\\ 88\\ 88\\ 88$	$\begin{array}{c} 24\\ 21\\ 54\\ 6\\ 11\\ 4\\ 6\\ 40\\ 3\\ 19\\ 13\\ 8\\ 6\\ 22\\ 1\\ 148\\ 15\\ 5\\ 7\\ 19\\ 59\\ 24\end{array}$	$\begin{array}{c} 261 \\ 5 \\ 2 \\ 124 \\ 9 \\ 11 \\ 16 \\ 5 \\ 25 \\ 15 \\ 4 \\ 3 \\ 5 \\ 15 \\ 4 \\ 8 \\ 5 \\ 3 \\ 4 \\ 8 \\ 4 \\ 5 \\ 1 \\ 2 \\ 14 \\ 1 \\ 2 \\ 14 \\ 1 \\ 7 \\ - 13 \end{array}$	154 1052 4 6 2 14 10 1 10 1 - - - 3 2 24 4 1 1 2 - 5 2 8	59 2 - 8 8 8 4 6 - 2 3 1 2 1 - 2 1 1 - 2 1 1 - - 2 3 3 - - - - - - - - - - - - - - -	115 52 10 3 13 8 6 2 2 1 1 12 4 9 4 6 6 - 1 32 6 - - 10 51 10 51 10 3 13 8 6 2 2 1 1 12 4 9 4 6 6 - 10 3 13 8 6 2 10 3 13 8 6 2 10 3 13 8 6 2 10 3 13 8 6 2 10 3 13 8 6 2 10 3 13 8 6 2 10 3 13 8 6 2 10 10 3 13 8 6 2 10 10 3 13 8 6 2 11 1 12 10 10 3 13 8 6 2 11 1 12 10 11 12 10 11 12 10 11 12 10 11 12 10 11 12 10 11 11 12 10 11 11 11 11 11 11 11 11 11 11 11 11	MOUNTAIN Albuquerque, N.M. Colo. Springs, Colo Denver, Colo. Las Vegas, Nev. Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, Utah Tucson, Ariz. PACIFIC Berkeley, Calif. Fresno, Calif. Glendale, Calif. Glendale, Calif. Glendale, Calif. Glendale, Calif. Los Angeles, Calif. Portland, Oreg. Sacramento, Calif. San Diego, Calif. San Diego, Calif. San Francisco, Calif. Santa Cruz, Calif.	b. 39 96 127 21 192 15 89 117 1,870 187 22 57 66 551 28 255 28 129 165 148	$507 \\ 65 \\ 30 \\ 54 \\ 67 \\ 16 \\ 117 \\ 11 \\ 60 \\ 87 \\ 1,200 \\ 100 \\ 77 \\ 16 \\ 355 \\ 42 \\ 342 \\ 20 \\ 92 \\ 107 \\ 85 \\ 59 \\ 91 \\ 12 \\ 101 \\ 48 \\ 63 \\ 7,384 \\ \end{cases}$	165 19 36 4 45 3 17 19 329 5 27 4 10 11 90 32 32 32 30 27 5 17 8 9 2,219	83 10 4 14 20 1 21 6 7 234 2 9 1 8 23 8 2 3 9 19 24 15 3 21 15 3 21 3 8 1,297	25 3 1 6 4 - 5 - 4 2 6 3 - 4 2 1 2 1 4 5 3 3 6 1 5 - 2 467	15 2 1 3 3 4 1 2 2 3 3 1 2 2 9 1 5 2 2 4 6 6 1 1 2 276	45 4 4 6 3 12 5 7 120 17 2 4 30 3 5 12 13 2 14 1 6 5 5 622

TABLE III. Deaths in 121 U.S. cities,* week ending August 21, 1993 (33rd Week)

*Mortality data in this table are voluntarily reported from 121 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

[†]Pneumonia and influenza.

⁹Because of changes in reporting methods in these 3 Pennsylvania cities, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. ¹Total includes unknown ages.

U: Unavailable.

Current Trends

Cigarette Smoking-Attributable Mortality and Years of Potential Life Lost — United States, 1990

Cigarette smoking is the single most preventable cause of premature death in the United States (1). An estimated 390,000 smoking-attributable deaths in the United States occurred in 1985 (1), and more than 434,000 deaths occurred in 1988 (2); in 1988, an estimated 1,198,887 years of potential life lost (YPLL) before age 65 were attributed to smoking (2). To estimate the national impact of cigarette smoking on mortality and YPLL, calculations were performed using the Smoking-Attributable Mortality, Morbidity, and Economic Cost (SAMMEC) software (3). This report summarizes the results of this analysis.

SAMMEC uses attributable risk formulas to estimate the number of deaths from neoplastic, cardiovascular, respiratory, and pediatric diseases associated with cigarette smoking (3). Estimates for adults (aged \geq 35 years) and infants (aged <1 year) were based on 1990 mortality data, the 1990 prevalence of cigarette smoking among adults, and 1989 data on smoking prevalence among pregnant women from CDC's National Center for Health Statistics (4,5; CDC, unpublished data, 1993). The number of burn deaths was obtained from the National Fire Protection Association (6), and estimates of lung cancer deaths from environmental tobacco smoke (ETS) among nonsmokers were obtained from an Environmental Protection Agency report (7). The YPLL to age 65 years and to life expectancy were calculated using standard methodology (3), and smoking-attributable mortality (SAM) and YPLL rates were age-adjusted to the 1980 U.S. population to allow more accurate comparisons with 1988 SAM and YPLL.

During 1990, 418,690 U.S. deaths (approximately 20% of all deaths) were attributed to smoking (Table 1). Overall, approximately twice as many deaths occurred among males as among females. A total of 179,820 of these deaths resulted from cardiovascular diseases; 151,322*, neoplasms; 84,475, respiratory diseases; and 1711, diseases among infants. Lung cancer (119,920 deaths*), ischemic heart disease (98,921 deaths), and chronic airway obstruction (48,982 deaths) accounted for the most deaths; combined, these conditions were responsible for 64.0% of all SAM.

Cigarette smoking resulted in 1,152,635 YPLL before age 65 years and 5,048,740 YPLL to life expectancy (Table 2). Compared with SAM and YPLL during 1988 (2), SAM declined by 3.6% and YPLL to age 65 years by 3.9% during 1990. SAM rates, total YPLL, and YPLL rates were higher for males than for females.

Reported by: Public Health Practice Program Office; Epidemiology Br, Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.

Editorial Note: The slight decline in SAM during 1990 compared with 1988 primarily reflects the 10.4% decline in deaths from cardiovascular disease. The rate of these deaths in the United States has decreased substantially since 1968 (*8*). In contrast, deaths from lung cancer increased by 4.4% and deaths from chronic obstructive pulmonary disease by 4.8%. SAM from these two conditions continue to increase

^{*}Includes deaths from ETS.

Cigarette Smoking — Continued

TABLE 1. Relative risks* (RR) for death attributed to smoking and smoking-attributable mortality (SAM) for current and former smokers, by disease category and sex — United States, 1990

	Ma	ale			Female		
	R	R			RR		
Disease category	Current	Former		Current	Former		Total
(ICD-9 code) [†]	smokers	smokers	SAM	smokers	s smokers	SAM	SAM
Adult diseases (persons aged							
≥ <i>35 yrs)</i> Neoplasms							
Lip, oral cavity, pharynx							
(140–149)	27.5	8.8	5,033	5.6	2.9	1,442	6,475
Esophagus (150)	7.6	5.8	5,668	10.3	3.2	1,616	7,284
Pancreas (157)	2.1	1.1	2,667	2.3	1.8	3,447	6,114
Larynx (161)	10.5	5.2	2,379		11.9	611	2,990
Trachea, lung, bronchus			_,				_,
(162)	22.4	9.4	81,179	11.9	4.7	35,741	116,920
Cervix uteri (180)	NA [§]	NA	ŃA	2.1	1.9	1,294	1,294
Urinary bladder (188)	2.9	1.9	3,046		1.9	980	4,026
Kidney, other urinary (189)	3.0	2.0	2,866		1.2	353	3,219
Cardiovascular diseases			,				
Hypertension (401–404)	1.9	1.3	3.299	1.7	1.2	2,151	5,450
Ischemic heart disease	,		0,277			2,.01	57.55
(410–414)							
Persons aged 35–64 yrs	2.8	1.8	26,431	3.0	1.4	7,701	34,132
Persons aged ≥65 yrs	1.6	1.3	38,918	1.6	1.3	25,871	64,789
Other heart diseases	1.0	1.5	50,710	1.0	1.0	20,071	04,707
(390–398, 415–417,							
420–429)	1.9	1.3	23,295	1.7	1.2	12,019	35,314
Cerebrovascular diseases	1.7	1.0	20,270		1.2	12,017	00/011
(430–438)							
Persons aged 35–64 yrs	3.7	1.4	4,557	4.8	1.4	4,114	8,671
Persons aged ≥65 yrs	1.9	1.3	10,421	1.5	1.0	4,189	14,610
Atherosclerosis (440)	4.1	2.3	3,737	3.0	1.3	2,675	6,412
Aortic aneurysm (441)	4.1	2.3	5,913	3.0	1.3	1,382	7,295
Other arterial disease	7.1	2.0	0,710	0.0	1.5	1,002	1,2,0
(442–448)	4.1	2.3	2,032	3.0	1.3	1,115	3,147
Respiratory diseases		2.0	2,002	0.0	1.0	1,110	0,117
Pneumonia and influenza							
(480–487)	2.0	1.6	11,292	2.2	1.4	7,881	19,173
Bronchitis, emphysema	2.0	1.0	11,272	2.2	1.4	7,001	17,175
(491–492)	9.7	8.8	9,324	10.5	7.0	5,541	14,865
Chronic airway	7.1	0.0	7,524	10.0	7.0	0,041	14,000
obstruction (496)	9.7	8.8	30,385	10.5	7.0	18,597	48,982
Other respiratory	7.7	0.0	00,000	10.0	7.0	10,077	40,702
diseases (010–012, 493)	2.0	1.6	787	2.2	1.4	668	1,455
Pediatric diseases (persons	2.0	1.0	101	2.2		000	1,100
aged <1 yr)							
Short gestation, low							
birth weight (765)	1	.8	285		1.8	222	507
Respiratory distress		.0	200		1.0		007
syndrome (769)	1	.8	219		1.8	141	360
Other respiratory conditions	•	.0	217		1.0		000
of newborn (770)	1	.8	214		1.8	160	374
Sudden infant death	•	-					••••
syndrome (798)	1	.5	288		1.5	182	470
Burn deaths [¶]	•	-	863			499	1,362
Environmental tobacco			000			777	1,002
smoke deaths**			1,055			1,945	3,000
							-
Total			276,153			142,537	418,690

*Relative to never smokers.

[†]International Classification of Diseases, Ninth Revision.

[§]Not applicable.

¹Source: National Fire Protection Association, 1993 (6).

**Deaths among nonsmokers from lung cancer attributable to environmental tobacco smoke (Environmental Protection Agency, 1992 [7]).

	SAM		Smoking-attribu before age		Smoking-attributable YPLI to life expectancy			
Category	Estimated no.	Rate	Estimated no.	Rate	Estimated no.	Rate		
Ven Women nfants	275,147 141,832 1,711	527.8 224.8 NA¶	732,389 308,801 111,445	1,919.1 764.6 NA	3,124,208 1,797,024 127,508	6,233.7 3,070.7 NA		
Fotal	418,690	364.5	1,152,635	1,325.8	5,048,740	4,541.3		

TABLE 2. Estimated number and age-adjusted rates* of smoking-attributable mortality (SAM) and smoking-attributable

*Per 100,000 persons aged ≥35 years, adjusted to the 1980 U.S. population. [†]Men and women=aged ≥35 years; infants=aged <1 year. [§]SAM rates and YPLL estimates and rates do not include 3000 deaths from passive smoking because such data were not available. [¶]Not available.

Cigarette Smoking — Continued

because of the long latency period between the onset of smoking and the development of disease.

The higher SAM and larger number of YPLL among males is consistent with previous reports (1,2). Men in the United States are more likely to smoke and to smoke more cigarettes per day than women (1,4). However, the smoking prevalence among men has declined substantially since 1965 (1). The smoking prevalence among women, after increasing in the 1960s, also has declined since the late 1970s (1). Therefore, future estimates of SAM and YPLL will most likely indicate a smaller difference between men and women.

The SAM and YPLL described in this report may be underestimated for at least four reasons. First, these estimates are based on current smoking prevalence data, whereas most smoking-attributable deaths during 1990 resulted from the higher smoking prevalence during earlier decades (2). Second, the SAM estimate for infants may be substantially underestimated because previous research suggests that approximately 10% of the 38,351 infant deaths that occurred during 1990 may be attributable to smoking (1,9). Third, the SAM estimates do not include deaths from other conditions, such as leukemia (2) and peptic ulcer disease (1), that also may be associated with smoking. Finally, these estimates do not include mortality caused by cigar smoking, pipe smoking, or smokeless tobacco use. The SAM and YPLL estimates in this report are not adjusted for confounders (e.g., alcohol), which may lower the estimates for laryngeal and certain upper gastrointestinal cancers (1).

The decrease in the prevalence of cigarette smoking since the 1960s has contributed to the decline in SAM (1,4). Maintaining this decline will require continued reduction in the prevalence of smoking. The human and economic costs associated with smoking require continued vigorous efforts to prevent the initiation of smoking, to encourage smoking cessation, and to protect nonsmokers from the adverse effects of ETS. Because many factors influence both smoking initiation and smoking cessation, multiple approaches are necessary (1) including 1) school-based health education; 2) reducing minors' access to tobacco products; 3) more extensive counseling by health-care providers about smoking cessation; 4) developing and enacting strong, clean indoor air policies and laws; 5) restricting or eliminating advertising targeted toward persons aged <18 years (10); and 6) increasing tobacco excise taxes.

References

- 1. CDC. Reducing the health consequences of smoking: 25 years of progress—a report of the Surgeon General, 1989. Rockville, Maryland: US Department of Health and Human Services, Public Health Service, 1989; DHHS publication no. (CDC)89-8411.
- 2. CDC. Smoking-attributable mortality and years of potential life lost—United States, 1988. MMWR 1991;40:62–3,69–71.
- Shultz JM, Novotny TE, Rice DP. Smoking-Attributable Mortality, Morbidity, and Economic Cost (SAMMEC) version 2.1 [Software and documentation]. Atlanta: US Department of Health and Human Services, Public Health Service, CDC, 1992.
- 4. CDC. Cigarette smoking among adults—United States, 1990. MMWR 1992;41:354–5,361–2.
- 5. CDC. Pregnancy risks determined from birth certificate data—United States, 1989. MMWR 1992;41:556–63.
- 6. Miller AL. The U.S. smoking-material fire problem through 1990: the role of lighted tobacco products in fire. Quincy, Massachusetts: National Fire Protection Association, 1993.
- 7. US Environmental Protection Agency. Respiratory health effects of passive smoking: lung cancer and other disorders. Washington, DC: US Environmental Protection Agency, Office of Health and Environmental Assessment, Office of Atmospheric and Indoor Air Programs, 1992; publication no. EPA-600/6-90/006F.

Cigarette Smoking — Continued

- 8. American Heart Association. 1993 Heart and stroke facts statistics. Dallas: American Heart Association, 1992.
- 9. NCHS. Advance report of final mortality statistics, 1990. Hyattsville, Maryland: US Department of Health and Human Services, Public Health Service, CDC, 1993. (Monthly vital statistics report; vol 41, no. 7, suppl).
- 10. Public Health Service. Healthy people 2000: national health promotion and disease prevention objectives—full report, with commentary. Washington, DC: US Department of Health and Human Services, Public Health Service, 1991; DHHS publication no. (PHS)91-50212.

Notice to Readers

Announcement of Eighth National Conference on Chronic Disease Prevention and Control

CDC, the Association of State and Territorial Health Officials, and the Association of State and Territorial Chronic Disease Program Directors will cosponsor the Eighth National Conference on Chronic Disease Prevention and Control, "The Role of Chronic Disease Prevention and Control in a Changing Health Environment." The conference will be November 17–19, 1993, in Kansas City, Missouri, and is open to the public.

The conference will emphasize interactions among federal, state, and local health departments; voluntary health agencies; and professional organizations. Topics will include worksite health promotion, nutrition and health, chronic disease and young persons, diabetes epidemiology, cancer epidemiology, older adults and their health, cardiovascular disease epidemiology, tobacco and health, use of local data for decision making, building community partnerships for healthy behavioral change in schools, and pitfalls of community intervention.

Additional information is available from CDC's National Center for Chronic Disease Prevention and Health Promotion, Mailstop K-43, 4770 Buford Highway, NE, Atlanta, GA 30341-3724; telephone (404) 488-5390; fax (404) 488-5962.

Erratum: Vol. 42, No. SS-3

In the *CDC Surveillance Summaries* report, "Surveillance for Gonorrhea and Primary and Secondary Syphilis Among Adolescents—United States, 1981–1991," the last column of Table 2 (page 4) contained an error. In the column "Total Population, Female," the rate for the South should be *1479.4*.

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available on a paid subscription basis from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 783-3238.

The data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the succeeding Friday. Inquiries about the *MMWR* Series, including material to be considered for publication, should be directed to: Editor, *MMWR* Series, Mailstop C-08, Centers for Disease Control and Prevention, Atlanta, GA 30333; telephone (404) 332-4555.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without special permission; citation as to source, however, is appreciated.

Acting Director, Centers for Disease Control and Prevention Walter R. Dowdle, Ph.D.
Acting Director, Epidemiology Program Office Barbara R. Holloway, M.P.H.
Editor, *MMWR* Series Richard A. Goodman, M.D., M.P.H.
Managing Editor, *MMWR* (weekly) Karen L. Foster, M.A.
Writers-Editors, *MMWR* (weekly) David C. Johnson Patricia A. McGee Darlene D. Rumph Caran R. Wilbanks

☆U.S. Government Printing Office: 1993-733-131/83026 Region IV